← Back to feed

Sareum Holdings

SAR · AIM · Health Care · mcap £43m today

All announcements

All RNS · 16 Key events · 13

02 Sep 26

Exercise of Warrants

Cambridge, UK, 2 September 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received notices to exercise certain warrants to...
RNS 9752730 ↗
19 Aug 26

Exercise of Warrants

Cambridge, UK, 19 August 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received notices to exercise certain warrants to...
RNS 9730380 ↗
07 Aug 26

Exercise of Warrants

Cambridge, UK, 7 August 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received notices to exercise certain warrants to...
RNS 9711353 ↗
20 Jul 26

Completion of Dosing in Toxicology Programme

Completion of Dosing in Phase 2-Enabling Toxicology Programme for SDC-1801
RNS 9675797 ↗
22 Jun 26

Publication of Phase 1 data on SDC-1801 in BJCP

Publication of Phase 1 clinical data on SDC-1801 in British Journal of Clinical Pharmacology
RNS 9629736 ↗
01 May 26

Exercise of Warrants

Cambridge, UK, 1 May 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received notice to exercise certain warrants to...
RNS 9547958 ↗
12 Mar 26

Half-year Results

Half-Year Report for the Six Months Ended 31 December 2025
RNS 9470266 ↗
17 Feb 26

Restart of Phase 2-enabling toxicology programme

Restart of Phase 2-enabling toxicology programme for SDC-1801
RNS 9433548 ↗
09 Dec 25

Result of AGM

Cambridge, UK, 9 December 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, held its Annual General Meeting ("AGM") today and all resolutions were...
RNS 9285885 ↗
09 Dec 25

Annual General Meeting Statement

Cambridge, UK, 9 December 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer publishes an update on operations and pipeline progress ahead of its...
RNS 9283630 ↗
30 Oct 25

Appointment of Joint Corporate Broker

Cambridge, UK, 30 October 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce the appointment of Singer Capital Markets as...
RNS 9202843 ↗
23 Oct 25

Final Results

Preliminary Results for the Year Ended 30 June 2025
RNS 9188570 ↗
10 Oct 25

Update on toxicology study for SDC-1801

Cambridge, UK, 10 October 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has discontinued its 16-week GLP preclinical...
RNS 9162257 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.